Gene Expression Changes Reflect Clinical Response in a Placebo-Controlled Randomized Trial of Abatacept in Patients with Diffuse Cutaneous Systemic Sclerosis

Authors

Eliza F. Chakravarty, Oklahoma Medical Research Foundation
Viktor Martyanov, Dartmouth College
David Fiorentino, Stanford University
Tammara A. Wood, Dartmouth College
David J. Haddon, Stanford University
Justin A. Jarrell, Stanford University
Paul Utz, Stanford University
Mark Genovese, Stanford University
Michael Whitfield, Dartmouth College
Lorinda Chung, Stanford University

Document Type

Article

Publication Date

2015

Publication Title

Arthritis Research and Therapy

Department

Geisel School of Medicine

Abstract

Systemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis of the skin and internal organs. We sought to assess the clinical and molecular effects associated with response to intravenous abatacept in patients with diffuse cutaneous systemic.

DOI

10.1186/s13075-015-0669-3

Dartmouth Digital Commons Citation

Chakravarty, Eliza F.; Martyanov, Viktor; Fiorentino, David; Wood, Tammara A.; Haddon, David J.; Jarrell, Justin A.; Utz, Paul; Genovese, Mark; Whitfield, Michael; and Chung, Lorinda, "Gene Expression Changes Reflect Clinical Response in a Placebo-Controlled Randomized Trial of Abatacept in Patients with Diffuse Cutaneous Systemic Sclerosis" (2015). Dartmouth Scholarship. 508.
https://digitalcommons.dartmouth.edu/facoa/508